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1  | INTRODUCTION, RESULTS, DISCUSSION
Cardiovascular disease (CVD) is a prevalent disease in the older pop‐
ulation. The incidence of atherosclerotic coronary artery disease 
(CAD) increases with age and is present in over 50% of people over 
60 years old (North & Sinclair, 2012). As such, older patients have a 
higher incidence of MI, which is accompanied by increased morbidity 
and mortality (Mehta et al., 2001).
Cellular senescence is classically defined as the irreversible cell 
cycle arrest of somatic cells. While senescence can act as a potent an‐
titumour mechanism, recent studies have shown that senescent cells 
accumulate in several tissues with age where they contribute to age‐
dependent tissue dysfunction and several age‐related diseases (de 
Magalhaes & Passos, 2018; Kirkland & Tchkonia, 2017). Senescent 
cells are thought to contribute to aging via a pro‐oxidant phenotype 
(Passos et al., 2010) and the secretion of a senescence‐associated 
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Abstract
Cardiovascular disease is the leading cause of death in individuals over 60 years old. 
Aging is associated with an increased prevalence of coronary artery disease and a 
poorer prognosis following acute myocardial infarction (MI). With age, senescent 
cells accumulate in tissues, including the heart, and contribute to age‐related pathol‐
ogies. However, the role of senescence in recovery following MI has not been inves‐
tigated. In this study, we demonstrate that treatment of aged mice with the senolytic 
drug, navitoclax, eliminates senescent cardiomyocytes and attenuates profibrotic 
protein expression in aged mice. Importantly, clearance of senescent cells improved 
myocardial remodelling and diastolic function as well as overall survival following MI. 
These data provide proof‐of‐concept evidence that senescent cells are major con‐
tributors to impaired function and increased mortality following MI and that senolyt‐
ics are a potential new therapeutic avenue for MI.
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secretory phenotype (SASP) (Coppe et al., 2008), which is pro‐in‐
flammatory, profibrotic and can also promote senescence in sur‐
rounding cells (Nelson et al., 2012).
Senescence has been shown to occur in the heart during aging 
(Anderson et al., 2019) and contributes to the pathophysiology of a num‐
ber of CVDs, as clearance of senescent cells in aged and atherosclerotic 
mice using both genetic and pharmacological approaches improves 
vascular and myocardial function and attenuates age‐dependent re‐
modelling (Anderson et al., 2019; Roos et al., 2016; Zhu et al., 2015). 
However, the impact of senescent cells in MI has not been investigated 
thus far. In this study, we hypothesise that senescent cells contribute to 
the poor prognosis and survival of aged individuals following MI.
F I G U R E  1  Aged	mice	display	increased	CM	senescence,	CM	hypertrophy,	increased	TGFβ2 expression and functional characteristics 
of myocardial aging, which are attenuated by navitoclax treatment. (a) Experimental design. (b) Percentage p16+ CMs by RNA in situ 
hybridization. Arrow indicates p16 expressing CMs (p16 red, troponin‐C green, DAPI blue), n = 8 per group. Scale bars = 50 µm. (c) WGA 
staining and quantification of CM cross‐sectional area, n	=	6–10	per	group.	(d)	TGFβ2 protein expression, n = 4–5 per group. (e) Examples of 
individual short axis cine‐MR images. Analysis of (f) left ventricular mass and (g) ejection fraction. (h) % change in wall thickness, n	=	14–34	
per	group.	For	c	and	d,	scale	bars	=	100	µm.	Data	are	mean	±	SEM, ***p < 0.001; **p < 0.01; * p < 0.05 using Student's t test or one‐way 
ANOVA
F I G U R E  2   Navitoclax treatment improves survival and functional outcome following MI. (a) Kaplan–Meier survival curve following MI, 
n = 20–45 per group. Dotted line indicates survival between the age of 104–109 weeks in a cohort of vehicle‐treated mice that received no 
MI (n = 9). (b) Examples of individual short axis cine‐MR images post‐MI. ED = end diastole, ES = end systole. (c) Ejection fraction at 1 and 
4 weeks post‐MI, n = 9–15 per group. (d) Relative change in ejection fraction between 1 and 4 weeks post‐MI, n = 7–11 per group. Data are 
mean	±	SEM, ***p < 0.001; **p < 0.01; * p < 0.05 using one‐way ANOVA
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Previously we found that in addition to clearing senescent cells, 
navitoclax treatment reduced fibrosis and cardiomyocyte (CM) hy‐
pertrophy in aged mice (Anderson et al., 2019) and considered that 
these beneficial effects may help to improve outcomes in aged mice 
following MI. We therefore performed a more detailed longitudinal 
study to examine this possibility and to explore potential mecha‐
nisms (detailed methods are included in Appendix S1).
Histological analysis was performed on a cohort of nonin‐
farcted mice, to assess the baseline effects of navitoclax treat‐
ment (50 mg kg−1 day−1	 in	 the	 regime	 shown	 in	 Figure	 1a).	 In	
addition to decreasing CM hypertrophy, treatment reduced mark‐
ers of CM senescence, indicating clearance of senescent cells 
from	the	hearts	of	treated	aged	mice	(Figure	1b–c).	Furthermore,	
we found a significant reduction in expression of profibrotic 
TGFβ2	(Figure	1d),	which	we	previously	identified	as	a	key	com‐
ponent	of	CM	SASP	(Anderson	et	al.,	2019).	Functionally,	navito‐
clax treatment significantly reduced the age‐dependent increase 
in	 left	 ventricular	 (LV)	 mass	 (Figure	 1f)	 but	 did	 not	 impact	 on	
ejection	fraction	(EF)	(Figure	1g).	Aged	mice	also	exhibited	a	de‐
crease in the percentage change in diastole versus end systole 
LV wall thickness, indicating an increased LV rigidity compared 
with young animals, which was also partly rescued by navitoclax 
treatment	 (Figure	 1h).	 Clinically,	 increased	 ventricle	 stiffness	 is	
related to fibrosis and hypertrophy during aging, is symptomatic 
of diastolic dysfunction and is observed in heart failure with pre‐
served ejection fraction patients (Borlaug, 2014).
To investigate whether treatment with navitoclax improved out‐
come following MI, mice from each group were then subjected to 
ligation of the left anterior descending coronary artery (LAD), which 
mimics the pathophysiology of MI (Redgrave et al., 2017).
We observed that aged mice had significantly higher mortal‐
ity rates following MI (60% over 5 weeks) compared with young 
mice and that this outcome was rescued by prior navitoclax treat‐
ment	 (Figure	2a).	This	high	mortality	also	contrasts	with	the	 low	
mortality observed in a cohort of aged mice that received no MI 
(Figure	2a)	and	our	previously	published	data	that	demonstrated	
a low mortality in male C57BL/6 mice between the same ages of 
104–109 weeks (Jurk et al., 2014). Together these data suggest 
that reduced survival in old mice following LAD‐ligation was a re‐
sult of the MI and was not due to aging alone. No difference in 
EF	was	observed	between	the	MI	groups	at	1	week.	However,	 in	
contrast	to	young	mice,	old	mice	show	a	significant	reduction	in	EF	
between 1 and 4 weeks post‐MI. Importantly, navitoclax was able 
to	rescue	this	functional	decline	(Figure	2b–d)	which	may	help	to	
explain	the	improved	survival	of	this	group.	Furthermore,	expres‐
sion of senescence markers p16 and p21 at 4 weeks following MI 
was reduced in the hearts of navitoclax‐treated mice, consistent 
with reduction of the senescence burden (supporting information 
Figure	S1A).
Collectively, this study shows that pharmacological clearance 
of senescent cells in aging mice alleviates age‐dependent myocar‐
dial remodelling and attenuates expression of profibrotic medi‐
ators. Navitoclax improved the maintenance of cardiac function 
following MI, ultimately increasing survival. An important limita‐
tion of this study is that our experimental strategy was not able 
to distinguish which senescent cell types are responsible for this 
effect, and it is possible that clearance of senescent cells in non‐
cardiac organs impact on survival following MI. We have focussed 
our attention on CMs in this study as our earlier findings showed 
that, in the heart, markers of senescence accumulate primarily in 
CMs during aging (Anderson et al., 2019). However, further stud‐
ies using animal models where senescent cells can be cleared in a 
cell‐type specific manner are required to formally show the con‐
tribution of senescent CMs to cardiac recovery post‐MI. As seno‐
lytics have now moved into clinical trials in other fibrotic diseases 
(Justice et al., 2019), we propose that senolytics may help to re‐
duce the morbidity and mortality associated with MI in the older 
population.
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